Breast Cancer Diagnostics Market Report 2026

Breast Cancer Diagnostics Market Overview

• Breast Cancer Diagnostics market size has reached to $5 billion in 2025 • Expected to grow to $7.28 billion in 2030 at a compound annual growth rate (CAGR) of 7.7% • Growth Driver: Government Funding And Breast Cancer Diagnostics A Path To Improved Healthcare • Market Trend: Ai Revolution In Breast Cancer Diagnosis Innovations In Breast Cancer Diagnostics Market • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Breast Cancer Diagnostics Market?

Breast cancer diagnostics refer to the various methods, tests, and procedures used to detect and diagnose breast cancer in individuals. These diagnostics help identify the presence of cancer cells in breast tissue, determine the stage of cancer, and guide treatment decisions. The main types of breast cancer diagnostics are imaging, biopsy, genomic tests, blood tests, and others. A biopsy is the process of removing a piece of tissue or a sample of cells from the body so that it can be tested in a laboratory. The technologies involved is fluorescent in situ hybridization (FISH), comparative genomic hybridization (CGH), immunohistochemical (IHC), and other technologies. The cancer types involved are BRCA breast cancer, ER and PR breast cancer, her type 2-breast cancer, EGFR mutation test breast cancer, and others. The diagnostic types involved are ionising breast imaging technologies and non-ionizing imaging technologies. The end-users involved are hospitals and clinics, cancer research centers, diagnostic laboratories, and ambulatory surgical centers.

What Is The Breast Cancer Diagnostics Market Growth Forecast?

The breast cancer diagnostics market size is expected to see strong growth in the next few years. It will grow to $7.28 billion in 2030 at a compound annual growth rate (CAGR) of 7.7%. The growth in the forecast period can be attributed to increasing adoption of precision oncology diagnostics, rising investments in AI-enabled diagnostic platforms, growing demand for minimally invasive testing, expansion of population-based screening programs, continuous advancements in molecular diagnostic technologies. Major trends in the forecast period include increasing adoption of ai-assisted imaging analysis, rising use of genomic and molecular testing, growing deployment of liquid biopsy techniques, expansion of advanced non-ionizing imaging modalities, enhanced focus on early and personalized diagnosis.

Global Breast Cancer Diagnostics Market Segmentation

1) By Type: Imaging, Biopsy, Genomic Tests, Blood Tests, Other Types 2) By Technology: Fluorescent In Situ Hybridization (FISH), Comparative Genomic Hybridization (CGH), Immunohistochemical (IHC), Other Technologies 3) By Cancer Type: BRCA Breast Cancer, ER And PR Breast Cancer, HER 2 Breast Cancer, Triple-Negative Breast Cancer, Other Cancer Types 4) By Diagnostic Type: Ionizing Breast Imaging Technologies, Non-ionizing Imaging Technologies 5) By End Users: Hospitals And Clinics, Cancer Research Centers, Diagnostic Laboratories, Ambulatory Surgical Centers Subsegments: 1) By Imaging: Mammography, Ultrasound Imaging, Magnetic Resonance Imaging (MRI), Positron Emission Tomography (PET), Tomosynthesis 2) By Biopsy: Needle Biopsy, Core Needle Biopsy, Fine Needle Aspiration Biopsy (FNA), Stereotactic Biopsy 3) By Genomic Tests: Oncotype DX, MammaPrint, PAM50, BRCA1 Or 2 Testing 4) By Blood Tests: Liquid Biopsy, Circulating Tumor DNA (ctDNA) Tests, Circulating Tumor Cells (CTCs) Tests 5) By Other Types: Hormone Receptor Tests, HER2 Tests, Genetic Mutation Testing

What Is The Driver Of The Breast Cancer Diagnostics Market?

Government initiatives and funding for breast cancer are expected to propel the growth of the breast cancer diagnostics market going forward. A government initiative and funding are a type of government financial support given to selected entities with ideas or projects that contribute to and improve public services and the economy. Government initiatives and funding play a critical role in supporting breast cancer research, prevention, and treatment, with various program being implemented to raise awareness, promote early detection through screening and mammography services, and provide financial assistance to underserved communities for breast cancer testing and treatment. For instance, The Australian Government Department of Health (DoH), the Australia-based Government agency, in its budget for 2022-23, they allocated $40.7 million to enhance the accessibility of testing and screening services for various types of cancers, compensating for setbacks caused by the COVID-19 pandemic, and enabling timely referrals, prompt diagnosis, and early intervention, comprising an allocation of $9.7 million specifically for breast cancer screening. Therefore, government initiatives and funding for breast cancer are driving the growth of the breast cancer diagnostics industry.

Key Players In The Global Breast Cancer Diagnostics Market

Major companies operating in the breast cancer diagnostics market are Abbott Laboratories, Myriad Genetics Inc., Hologic Inc., Koninklijke Philips N.V., Fujifilm Holdings Corporation, GE Healthcare, Thermo Fisher Scientific Inc., Siemens AG, NanoString Technologies Inc., Gamma Medica Inc., Aurora Imaging Technology Inc., Dilon Technologies Inc., Exact Sciences Corporation, F. Hoffmann-La Roche Ltd., Micrima Limited, Provista Diagnostics Inc., Leica Biosystems Nussloch GmbH, bioTheranostics Inc., Bio-Rad Laboratories Inc., Illumina Inc., Biocept Inc., Quest Diagnostics Incorporated, Agilent Technologies Inc., Cepheid, Guardant Health Inc., Invitae Corporation, Natera Inc., NeoGenomics Laboratories Inc., Oncocyte Corporation, PerkinElmer Inc., Sysmex Corporation, Veracyte Inc.

Global Breast Cancer Diagnostics Market Trends and Insights

Major companies operating in the breast cancer diagnostics market are focusing on developing innovative AI-based diagnostic solutions, such as advanced pathology scoring platforms, to boost accuracy, streamline workflows, and enable personalized treatment planning. AI-based diagnostic platforms refer to technologies that employ machine learning and deep-learning algorithms to analyze medical imaging, pathology slides, or clinical data, and deliver diagnostic insights or risk stratifications that support clinical decision-making. For instance, in September 2024, Ibex Medical Analytics, an Israel-based digital pathology company, launched its expanded AI platform for breast cancer diagnostics, introducing a fully automated zero-click HER2 immunohistochemistry (IHC) scoring feature in its Ibex Breast HER2 module. This tool identifies invasive cancer areas, classifies HER2 expression levels (0, 1+, 2+, 3+), and supports breast cancer diagnosis and treatment-pathway decisions with improved accuracy and workflow efficiency.

What Are Latest Mergers And Acquisitions In The Breast Cancer Diagnostics Market?

In July 2024, Hologic Inc., a US-based company that offers healthcare technology acquired Endomagnetics Ltd. for $310 million. With this acquisition, Hologic aims to enhance its breast surgery portfolio with Endomag's innovative wireless localization and lymphatic tracing solutions. Endomagnetics Ltd. is a UK-based company that offers advanced technologies for breast cancer diagnostics, including solutions for tissue localization and lymphatic tracing.

Regional Outlook

North America was the largest region in the breast cancer diagnostics market in 2025. Asia-Pacific was the second largest region in the breast cancer diagnostics industry. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain

What Defines the Breast Cancer Diagnostics Market?

The breast cancer diagnostics market consists of sales of instruments such as analyzer, reagents and others that are used for the diagnosis of breast cancer. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.